Author: digi

How to Develop SOPs for Institutional Ethics Committees

August 23, 2025

How to Develop SOPs for Institutional Ethics Committees Step-by-Step Guide to Creating SOPs for Institutional Ethics Committees Introduction: Why SOPs Are Crucial for Ethics Committees Standard Operating Procedures (SOPs) are foundational documents that govern the operations of Institutional Ethics Committees (IECs) or Institutional Review Boards (IRBs). SOPs not only ensure consistency, regulatory compliance, and quality…

Clinical Trial Transparency and Ethics, Ethical Review Standards

Ensuring Data Integrity in CRO Operations

August 23, 2025

digi

Ensuring Data Integrity in CRO Operations Data Integrity Oversight in CRO Operations: Regulatory Expectations and Best Practices Introduction: Why CRO Data Integrity Matters Data integrity is a cornerstone of clinical trial compliance. When trial functions are outsourced to Contract Research Organizations (CROs), sponsors remain accountable for ensuring data reliability under 21 CFR Part 312. FDA…

Clinical Trial Operations & Compliance, Vendor Oversight & CRO Compliance

Bioequivalence Study Requirements for BCS Class I Drugs: A Regulatory Perspective

August 23, 2025

digi

Bioequivalence Study Requirements for BCS Class I Drugs: A Regulatory Perspective Regulatory Expectations for Bioequivalence in BCS Class I Drugs Introduction to BCS Class I and Regulatory Implications The Biopharmaceutics Classification System (BCS) classifies drug substances based on solubility and intestinal permeability. BCS Class I drugs are characterized by high solubility and high permeability, making…

Bioavailability and Bioequivalence Studies (BA/BE), Regulatory Submission

Marketing Authorization Application (MAA) Best Practices

August 23, 2025

digi

Marketing Authorization Application (MAA) Best Practices Step-by-Step Best Practices for Successful MAA Submission in the EU Introduction: What Is an MAA and Why Strategy Matters A Marketing Authorization Application (MAA) is the regulatory gateway for obtaining approval to market a medicinal product in the European Union (EU) and European Economic Area (EEA). Overseen by the…

NDA/BLA/MAA Filings, Regulatory Submissions and Approvals

Role of Sponsors in eTMF Audit Trail Reviews

August 23, 2025

digi

Role of Sponsors in eTMF Audit Trail Reviews The Sponsor’s Role in Ensuring eTMF Audit Trail Compliance Why Sponsor Involvement in Audit Trail Reviews Is Critical In the context of clinical trial documentation, the sponsor is ultimately responsible for ensuring that the electronic Trial Master File (eTMF) is accurate, complete, and inspection-ready. One of the…

Audit Trails and Inspection Readiness, TMF and eTMF Audit Trails

Decentralized Clinical Trials in Rare Diseases: Opportunities and Risks

August 23, 2025

digi

Decentralized Clinical Trials in Rare Diseases: Opportunities and Risks Harnessing Decentralized Clinical Trials to Improve Access in Rare Disease Research The Rationale for Decentralization in Rare Disease Trials Rare disease trials face one central challenge: patient scarcity scattered across vast geographies. Traditional site-based clinical trials often fail to recruit sufficient participants due to travel limitations,…

Rare and Orphan Disease Trials, Trial Design & Methodology

Common Errors in Clinical Trial Results Reporting and How to Correct Them

August 23, 2025

digi

Common Errors in Clinical Trial Results Reporting and How to Correct Them Common Mistakes in Trial Results Reporting and How to Fix Them Introduction: Importance of Accurate Results Reporting Accurate reporting of clinical trial results on public registries such as ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) is a regulatory and ethical obligation….

Clinical Trial Registries and Result Disclosure, Results Posting Requirements

Applying Natural Language Processing to Identify Rare Disease Signals

August 23, 2025

digi

Applying Natural Language Processing to Identify Rare Disease Signals Leveraging NLP to Detect Rare Disease Indicators in Clinical Research Introduction to NLP in Rare Disease Research Rare disease clinical research faces the recurring problem of underdiagnosis and misdiagnosis, largely because traditional diagnostic codes and structured data fields fail to capture the nuanced descriptions of symptoms…

Data & Technology, Rare and Orphan Disease Trials

How to Document and Classify Deviations in CRO Processes

August 23, 2025

digi

How to Document and Classify Deviations in CRO Processes Best Practices for Documenting and Classifying CRO Deviations Introduction: The Importance of Structured Deviation Documentation Deviation management is a cornerstone of quality assurance in clinical trial operations. For Contract Research Organizations (CROs), effective documentation and classification of deviations are essential to maintain regulatory compliance, protect subject…

CRO Audits, CAPA, and Deviation Management, Deviation Handling in CROs

SOP for Insurance and Indemnity Requirements

August 23, 2025

digi

SOP for Insurance and Indemnity Requirements { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.clinicalstudies.in/insurance-and-indemnity-requirements” }, “@id”: “https://www.clinicalstudies.in/insurance-and-indemnity-requirements”, “headline”: “SOP for Insurance and Indemnity Requirements”, “name”: “SOP for Insurance and Indemnity Requirements”, “description”: “Comprehensive SOP defining insurance and indemnity requirements for clinical trials under TGA oversight, including sponsor responsibilities, site obligations, and compliance…

SOP for GCP, TGA — Unique SOPs